Kenneth P Johnson

Summary

Affiliation: University of Maryland
Country: USA

Publications

  1. ncbi Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data
    K P Johnson
    Maryland Center for MS, Baltimore, MD 21201, USA
    Acta Neurol Scand 111:42-7. 2005
  2. ncbi Control of multiple sclerosis relapses with immunomodulating agents
    Kenneth P Johnson
    Maryland Center for Multiple Sclerosis, University of Maryland, Baltimore, 11 S Paca Street, Suite 300A, Baltimore, Maryland 21201, USA
    J Neurol Sci 256:S23-8. 2007
  3. ncbi Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis
    Kenneth P Johnson
    University of Maryland, Baltimore, MD, USA
    Expert Rev Pharmacoecon Outcomes Res 9:205-14. 2009
  4. ncbi Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update
    Kenneth P Johnson
    University of Maryland Baltimore, Baltimore, Maryland 21201, USA
    Expert Opin Drug Metab Toxicol 6:643-60. 2010
  5. ncbi Natalizumab (Tysabri) treatment for relapsing multiple sclerosis
    Kenneth P Johnson
    Department of Neurology, University of Maryland Baltimore School of Medicine, Maryland Center for Multiple Sclerosis, Baltimore, Maryland 21201, USA
    Neurologist 13:182-7. 2007
  6. ncbi Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial
    Steven R Schwid
    University of Rochester, Department of Neurology, Rochester, NY 14642, USA
    J Neurol Sci 255:57-63. 2007
  7. ncbi Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial
    K P Johnson
    Department of Neurology, University of Maryland, Baltimore, MD 21201, USA. edu
    Mult Scler 9:585-91. 2003
  8. ncbi Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype
    Suhayl Dhib-Jalbut
    University of Maryland School of Medicine, Baltimore, MD 21201, USA
    J Neuroimmunol 140:163-71. 2003
  9. ncbi Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years
    M Chen
    University of Maryland School of Medicine, Baltimore, MD 21201, USA
    J Neurol Sci 201:71-7. 2002
  10. ncbi United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center
    J S Wolinsky
    Department of Neurology, The University of Texas-Houston, Health Science Center, 77030, USA
    Mult Scler 7:33-41. 2001

Detail Information

Publications14

  1. ncbi Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data
    K P Johnson
    Maryland Center for MS, Baltimore, MD 21201, USA
    Acta Neurol Scand 111:42-7. 2005
    ..To assess the long-term effectiveness of continuous glatiramer acetate (GA) therapy in relapsing-remitting multiple sclerosis (RRMS)...
  2. ncbi Control of multiple sclerosis relapses with immunomodulating agents
    Kenneth P Johnson
    Maryland Center for Multiple Sclerosis, University of Maryland, Baltimore, 11 S Paca Street, Suite 300A, Baltimore, Maryland 21201, USA
    J Neurol Sci 256:S23-8. 2007
    ..By reviewing the existing comparisons, clinicians will better understand the factors determining when to initiate therapy with an immunomodulator and how to determine which of these treatments may best suit their patients' needs...
  3. ncbi Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis
    Kenneth P Johnson
    University of Maryland, Baltimore, MD, USA
    Expert Rev Pharmacoecon Outcomes Res 9:205-14. 2009
    ..This article will review this evidence including data from very recent head-to-head clinical trials and pharmacoeconomic analyses of cost-effectiveness...
  4. ncbi Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update
    Kenneth P Johnson
    University of Maryland Baltimore, Baltimore, Maryland 21201, USA
    Expert Opin Drug Metab Toxicol 6:643-60. 2010
    ..Glatiramer acetate (GA), a complex polypeptides mixture and first member of the glatiramoid class, is a first-line therapy for relapsing MS. New glatiramoids are under development...
  5. ncbi Natalizumab (Tysabri) treatment for relapsing multiple sclerosis
    Kenneth P Johnson
    Department of Neurology, University of Maryland Baltimore School of Medicine, Maryland Center for Multiple Sclerosis, Baltimore, Maryland 21201, USA
    Neurologist 13:182-7. 2007
    ....
  6. ncbi Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial
    Steven R Schwid
    University of Rochester, Department of Neurology, Rochester, NY 14642, USA
    J Neurol Sci 255:57-63. 2007
    ....
  7. ncbi Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial
    K P Johnson
    Department of Neurology, University of Maryland, Baltimore, MD 21201, USA. edu
    Mult Scler 9:585-91. 2003
    ....
  8. ncbi Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype
    Suhayl Dhib-Jalbut
    University of Maryland School of Medicine, Baltimore, MD 21201, USA
    J Neuroimmunol 140:163-71. 2003
    ..Furthermore, some myelin-specific TCLs are able to recognize GA, with a tendency to produce more IL-5 than IFN-gamma, which would suggest a systemic modulatory effect of the drug...
  9. ncbi Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years
    M Chen
    University of Maryland School of Medicine, Baltimore, MD 21201, USA
    J Neurol Sci 201:71-7. 2002
    ....
  10. ncbi United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center
    J S Wolinsky
    Department of Neurology, The University of Texas-Houston, Health Science Center, 77030, USA
    Mult Scler 7:33-41. 2001
    ....
  11. ncbi Practical issues in the management of multiple sclerosis. Introduction
    Kenneth P Johnson
    Department of Neurology, University of Maryland School of Medicine, Baltimore, USA
    Neurology 58:S1-2. 2002
  12. ncbi Current therapy of multiple sclerosis
    K P Johnson
    Department of Neurology, University of Maryland School of Medicine, Baltimore, USA
    Hosp Pract (Minneap) 36:21-2, 25-8; discussion 28-9. 2001
    ..Ideally, however, drug therapy should be part of a multidisciplinary approach that also includes such elements as patient education and physical therapy...
  13. ncbi Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials
    Filippo Martinelli Boneschi
    Department of Neuroscience, Scientific Institute, University H San Raffaele, Milan, Italy
    Mult Scler 9:349-55. 2003
    ..It also suggests that GA efficacy is not significantly influenced by the patients' clinical characteristics at the time of treatment initiation...
  14. ncbi Relapses matter: the costs & consequences of multiple sclerosis relapses
    Patricia K Coyle
    Stony Brook University Medical Center, Stony Brook, New York, USA
    J Neurol Sci 256:S1-4. 2007